Clinical trial
Open access
Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia
Naval G. Daver
A. Zeidan
A. Stein
J. Zeidner
K. Maher
Emily Curran
Dale L. Bixby
W. Chai-Ho
Maximilian Stahl
Karen W. L. Yee
Don Stevens
S. Ito
Jana Reynolds
Patrick Medd
Emma Searle
Andrew Sochacki
M. Savoie
Steven Green
Kazunobu Kato
Robert Hernandez
Simon Metenou
Bo Ma
L. Pandite
Taylor H. Schreiber
D. Sallman
Medicine
Abstract
This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML).